American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)
    Meeting Abstract

    Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla Mercade, T.; Xie, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors
    Meeting Abstract

    Borad, M. J.; Schram, A. M.; Kim, R. D.; Kamath, S. D.; Sahai, V.; Dotan, E.; Kelley, R. K.; Ponz-Sarvise, M.; Oh, D. Y.; Yachnin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Solit, D. B.; Walch, H. S.; Chatila, W. K.; Maron, S. B.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Schultz, N.; Berger, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
    Meeting Abstract

    Cohen, R.; Raeisi, M.; Shi, Q.; Chibaudel, B.; Yoshino, T.; Zalcberg, J. R.; Adams, R.; Cremolini, C.; Van Cutsem, E.; Heinemann, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The significance of mucin on rectal MRI in patients with locally advanced rectal cancer being considered for watch-and-wait after neoadjuvant therapy
    Meeting Abstract

    Judge, S.; Malekzadeh, P.; Corines, M. J.; Gollub, M. J.; Horvat, N.; Saltz, L. B.; Cercek, A.; Romesser, P. B.; Crane, C. H.; Wei, I. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Lau, G.; Cheng, A. L.; Sangro, B.; Kudo, M.; Kelley, R. K.; Tak, W. Y.; Gasbarrini, A.; Reig, M.; Lim, H. Y.; Tougeron, D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Organ preservation and total neoadjuvant therapy for rectal cancer: Investigating long course chemoradiation versus short course radiation therapy
    Meeting Abstract

    Romesser, P. B.; Park, B. K.; Pappou, E.; Nemirovsky, D.; Alvarez, J.; Omer, D. M. R.; Sarkar, R.; Verheij, F. S.; Reyngold, M.; Wu, A. J. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS
    Meeting Abstract

    Strickler, J. H.; Cercek, A.; Ng, K.; Siena, S.; Andre, T.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J. M.; Coveler, A. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation
    Meeting Abstract

    Alvarez, J.; Cercek, A.; Mohan, N.; Ho, Y. J.; Zinovoy, M.; Reyngold, M.; Yaeger, R.; Hajj, C.; Fanta, C.; Roth O'Brien, D. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with gastrointestinal (GI) cancers
    Meeting Abstract

    Balogun, F.; Altoe, M.; O'Connor, C.; Chowdhury, N.; Cercek, A.; Lee, C. K.; Foote, M. B.; Kim, D.; Maron, S. B.; Kim, D. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save